This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heimann, R. Articles by Hellman, S. Search for Related Content PubMed PubMed Citation Articles by Heimann, R. Articles by Hellman, S.

Separating Favorable from Unfavorable Prognostic Markers in Breast Cancer: The Role of E-Cadherin

Department of Radiation and Cellular Oncology, The Pritzker School of Medicine, The University of Chicago, Chicago, Illinois 60637

Distant metastases are the major cause of morbidity and mortality in women with breast cancer. The ability to predict the metastatic proclivity is essential in choosing the optimal treatment. Tumor size and grade, which are frequently used markers in node-negative breast cancer patients, are inadequate markers for prognosis and individualized treatment design. The steps in metastatic progression include angiogenesis, invasion, and changes in adhesion characteristics. We developed a strategy for choosing biomarkers representing these steps in malignant progression to identify patients with occult metastases who will need chemotherapy and spare those women whose tumors have not developed the capacity to spread. To evaluate the added significance of E-cadherin to that of nm23-H1 and angiogenesis in determining metastatic proclivity, we used archival material from 168 node-negative breast cancer patients who were treated with mastectomy without any adjuvant chemotherapy or hormone therapy. Immunohistochemistry was used to detect E-cadherin and nm23-H1 expression, whereas angiogenesis was determined by microvessel count (MVC) after immunohistochemical staining. The median follow-up is 14 years. We found that E-cadherin is better in identifying the poor prognosis patients. The 14-year disease-free survival (DFS) is 84%, 80%, and 56% in patients with high, intermediate, and low E-cadherin. The worst prognosis group using nm23-H1 and MVC as biomarkers has a 14-year DFS of 62%. In this group, if E-cadherin is low, the 14-year DFS is further decreased to 44%. Nm23-H1 and MVC are better in identifying the good prognosis patients. The long-term DFS is >90% if MVC is low or if nm23-H1 is high. Multivariate analysis shows that E-cadherin, nm23-H1, and MVC are more significant prognostic biomarkers than tumor size or grade. Loss of E-cadherin appears to be a latter step in the metastatic progression compared to angiogenesis and the loss of nm23-H1 expression.

This article has been cited by other articles:

				K. L. Andarawewa, A. C. Erickson, W. S. Chou, S. V. Costes, P. Gascard, J. D. Mott, M. J. Bissell, and M. H. Barcellos-Hoff Ionizing Radiation Predisposes Nonmalignant Human Mammary Epithelial Cells to Undergo Transforming Growth Factor {beta} Induced Epithelial to Mesenchymal Transition Cancer Res., September 15, 2007; 67(18): 8662 - 8670. [Abstract] [Full Text] [PDF]

				S. Brouxhon, S. Kyrkanides, M. K. O'Banion, R. Johnson, D. A. Pearce, G. M. Centola, J.-n. H. Miller, K. H. McGrath, B. Erdle, G. Scott, et al. Sequential Down-regulation of E-Cadherin with Squamous Cell Carcinoma Progression: Loss of E-Cadherin via a Prostaglandin E2-EP2 Dependent Posttranslational Mechanism Cancer Res., August 15, 2007; 67(16): 7654 - 7664. [Abstract] [Full Text] [PDF]

				M. Harigopal, A. J. Berger, R. L. Camp, D. L. Rimm, and H. M. Kluger Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer Clin. Cancer Res., June 1, 2005; 11(11): 4083 - 4089. [Abstract] [Full Text] [PDF]

				L. K. Mell, J. J. Meyer, M. Tretiakova, A. Khramtsov, C. Gong, S. D. Yamada, A. G. Montag, and A. J. Mundt Prognostic Significance of E-Cadherin Protein Expression in Pathological Stage I-III Endometrial Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5546 - 5553. [Abstract] [Full Text] [PDF]

				C. C. Park, R. L. Henshall-Powell, A. C. Erickson, R. Talhouk, B. Parvin, M. J. Bissell, and M. H. Barcellos-Hoff Ionizing radiation induces heritable disruption of epithelial cell interactions PNAS, September 16, 2003; 100(19): 10728 - 10733. [Abstract] [Full Text] [PDF]

				M. Anders, R. Hansen, R.-X. Ding, K. A. Rauen, M. J. Bissell, and W. M. Korn Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor PNAS, February 18, 2003; 100(4): 1943 - 1948. [Abstract] [Full Text] [PDF]

				A N J Graham, P Maxwell, K Mulholland, A H Patterson, N Anderson, K G McManus, H Bharucha, and J A McGuigan Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination J. Clin. Pathol., March 1, 2002; 55(3): 184 - 189. [Abstract] [Full Text] [PDF]

				P. G. Corn, E. I. Heath, R. Heitmiller, F. Fogt, A. A. Forastiere, J. G. Herman, and T.-T. Wu Frequent Hypermethylation of the 5' CpG Island of E-Cadherin in Esophageal Adenocarcinoma Clin. Cancer Res., September 1, 2001; 7(9): 2765 - 2769. [Abstract] [Full Text] [PDF]

				J. Lundin, M. Lundin, K. Holli, V. Kataja, L. Elomaa, L. Pylkkanen, T. Turpeenniemi-Hujanen, and H. Joensuu Omission of Histologic Grading From Clinical Decision Making May Result in Overuse of Adjuvant Therapies in Breast Cancer: Results From a Nationwide Study J. Clin. Oncol., January 1, 2001; 19(1): 28 - 36. [Abstract] [Full Text] [PDF]

				F. Bertucci, R. Houlgatte, A. Benziane, S. Granjeaud, J. Adelaide, R. Tagett, B. Loriod, J. Jacquemier, P. Viens, B. Jordan, et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes Hum. Mol. Genet., December 1, 2000; 9(20): 2981 - 2991. [Abstract] [Full Text] [PDF]